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Abstract 37 
In this work a step forward in investigating the use of prescription drugs, namely erectile 38 
dysfunction products, at European level was taken by applying the wastewater-based 39 
epidemiology approach. 24-h composite samples of untreated wastewater were collected at 40 
the entrance of eight wastewater treatment plants serving the catchment within the cities of 41 
Bristol, Brussels, Castellón, Copenhagen, Milan, Oslo, Utrecht and Zurich. A validated 42 
analytical procedure with direct injection of filtered aliquots by liquid chromatography-43 
tandem mass spectrometry was applied. The target list included the three active 44 
pharmaceutical ingredients (sildenafil, tadalafil and vardenafil) together with 45 
(bio)transformation products and other analogues. Only sildenafil and its two human urinary 46 
metabolites desmethyl- and desethylsildenafil were detected in the samples with 47 
concentrations reaching 60ௗngௗL−1. The concentrations were transformed into normalized 48 
measured loads and the estimated actual consumption of sildenafil was back-calculated from 49 
these loads. In addition, national prescription data from five countries was gathered in the 50 
form of the number of prescribed daily doses and transformed into predicted loads for 51 
comparison. This comparison resulted in the evidence of a different spatial trend across 52 
Europe. In Utrecht and Brussels, prescription data could only partly explain the total amount 53 
found in wastewater; whereas in Bristol, the comparison was in agreement; and in Milan and 54 
Oslo a lower amount was found in wastewater than expected from the prescription data. This 55 
study illustrates the potential of wastewater-based epidemiology to investigate the use of 56 
counterfeit medication and rogue online pharmacy sales. 57 
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 60 
Highlights (3 to 5, max 85 characters): 61 
o Wastewater-based epidemiology successfully used to track counterfeit medication 62 
o Very sensitive LC-MS/MS method allows identification of targets at low ng L-1 level 63 
o Different spatial trends in sildenafil use were found across Europe 64 
 65 
1. Introduction 66 
The chemical analysis of raw wastewater with advanced mass spectrometry techniques allows 67 
the determination of human urinary biomarkers when these are excreted in sufficient 68 
concentrations and remain stable in their way along the sewer system (Castiglioni et al. 2012). 69 
The finding of specific biomarkers may reveal valuable near real-time information regarding a 70 
population’s lifestyle, illness, and exposure to external agents. Successful studies thus far 71 
have revealed the population’s level of oxidative stress (Ryu et al. 2015), its exposure to 72 
pesticides (Rousis et al. 2017), and to phthalate plasticizers (González-Mariño et al. 2017), its 73 
consumption of legal substances such as alcohol, nicotine or caffeine (Baz-Lomba et al. 2016, 74 
Ryu et al. 2016), its use of illicit drugs (Causanilles et al. 2017, Ort et al. 2014) and other 75 
psychoactive substances (Bade et al. 2017), and its intake of certain pharmaceuticals 76 
(Causanilles et al. 2016). 77 
The monitoring of active pharmaceutical ingredients (APIs) and their metabolites in 78 
wastewater offers an interesting value (van Nuijs et al. 2015). These substances have gone 79 
through a very detailed study and clinical trial before their final usage approval. Therefore the 80 
information regarding the absorbed dose after drug intake, the metabolic pathway and the 81 
excretion profile and rates in biological matrices is well known (Abed 2014). This 82 
information allows the selection of the appropriate target urinary biomarker in the application 83 
of wastewater-based epidemiology. Concentrations in untreated wastewater, considered a 84 
collective pooled urine sample, are then obtained as measured environmental concentration 85 
(MEC) of the unchanged product or its metabolites, which can be converted into 86 
environmental mass loads and then back-calculated into consumption estimates applying the 87 
appropriate correction factor. In addition, the number of dispensed pharmaceutical in the form 88 
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of defined daily doses (DDD) or product quantities dispensed by pharmacies or doctors can be 89 
obtained (in most cases, depending of the pharmaceutical and the country). From this data the 90 
average amount of mg of the API that have been legally dispensed per day can be calculated 91 
and transformed into a predicted environmental concentration (PEC) (Carballa et al. 2008, 92 
Verlicchi et al. 2014). 93 
The comparison between prescription data and wastewater loads may result in three different 94 
scenarios: (i) consumption estimated from wastewater load is lower than what would be 95 
expected from the dispensed data. This would represent the case of pharmaceuticals that have 96 
been less used than what it is prescribed or defined by the DDD; (ii) consumption estimated 97 
from wastewater load and the load expected from dispensed data are similar, which would 98 
represent the ideal situation, where there is no misuse; (iii) consumption estimated from 99 
wastewater load is higher than the load expected from the dispensed data. The third scenario 100 
represents the case of pharmaceuticals that are available in a counterfeit or falsified form and 101 
that can be acquired from other sources such as rogue online pharmacies or black market. 102 
This was the case observed for the phosphodiesterase type V inhibitor sildenafil, API in 103 
erectile dysfunction pharmaceuticals, in a study performed in the Netherlands in 2013 104 
(Venhuis et al. 2014b). Results showed that only one third to one half of the consumption 105 
estimated from wastewater loads could be related to the acquisition of the drug from legal 106 
sources (Venhuis et al. 2014a). 107 
However, the comparison needs to be handled with care, since other sources for discrepancy 108 
can be present. They might be related to the sewer system, with the incomplete release to the 109 
sewer system or elimination processes between the consumption point and the wastewater 110 
treatment plant, namely degradation, sorption and sedimentation (van Nuijs et al. 2015, 111 
Verlicchi et al. 2014). 112 
Erectile dysfunction is estimated to affect 25 to 35 million men over the age of 18 in Europe, 113 
according to the European Federation of Pharmaceutical Industries and Associations (EFPIA 114 
2017). It is a disease of increasing concern, since an aging population will result in higher 115 
prevalence. Despite the high number of men affected, it is still highly stigmatized, and users 116 
usually tend to hide their related drug use. Illegal trading with products from the internet and 117 
with counterfeit medicines is increasing (Chiang et al. 2017). However, the individuals 118 
purchasing medicines via the internet are for the most part not sufficiently aware of the risks 119 
they run in doing so (Keizers et al. 2016). Concerns about the quality of these products may 120 
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arise, specially towards the possible presence of impurities that may lead to poisoning if toxic 121 
(Johnston and Holt 2014), and an increased risk of side effects or overdosing. 122 
In this work the wastewater-based epidemiology approach was applied to assess the use of 123 
phosphodiesterase type V inhibitors in eight European cities accounting to almost 5 million 124 
inhabitant equivalents. To do so, 24-h composite wastewater samples were collected in each 125 
city for seven consecutive days and analysed by liquid chromatography coupled to tandem 126 
mass spectrometry. Measured concentrations in sample were converted into loads and back-127 
calculated to estimate consumption with known pharmacokinetic information. In addition, 128 
available data at national level of the number of prescribed or dispensed erectile dysfunction 129 
pharmaceuticals were gathered to discuss their correlation. 130 
 131 
2. Materials and methods 132 
The analytical methodology used to perform the wastewater chemical analysis was previously 133 
validated elsewhere (Causanilles et al. 2016). The chemicals and materials section can be 134 
found in the Supplementary Information (Section SI-1). 135 
2.1.Sample collection 136 
A week-monitoring sampling campaign was performed in March 2015 in eight European 137 
cities. For seven consecutive days 24-h influent composite samples were collected at the 138 
entrance of the wastewater treatment plants (WWTPs) serving the cities of Bristol, England; 139 
Brussels, Belgium; Castellon, Spain; Copenhagen, Denmark; Milan, Italy; Oslo, Norway; 140 
Utrecht, the Netherlands; and Zurich, Switzerland. The number of inhabitants included in the 141 
total catchment area under study represented almost 5 million people in Europe. Table SI-1 142 
compiles detailed information about the sample collection at the different locations: date of 143 
sample collection, influent flow (m3 24h-1), sampling mode and frequency, average 144 
wastewater temperature (°C), pH, biological and chemical oxygen demand (BOD5 and COD), 145 
total phosphate (Ptot), and nitrogen content as Kjeldahl (Ntot) and ammonia (NH4-N). 146 
2.2.Analytical methodology  147 
All samples were collected in high density polyethylene bottles, shipped frozen to KWR in 148 
Nieuwegein (NL) and stored in the dark at –20 °C until treatment. Samples were thawed and 149 
homogenized. Then a 10 mL aliquot was spiked with deuterated analogues to act as surrogate 150 
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and filtered with regenerated cellulose syringe filters. With no further pre-treatment a 100 µL 151 
aliquot of each sample was injected into the liquid chromatography coupled to triple 152 
quadruple mass spectrometer (Thermo Scientific TSQ Vantage, Thermo Electron, Bremen, 153 
Germany). Chromatographic separation was achieved with a XBridge C18 column (150 mm 154 
× 2.1 mm I.D., particle size 3.5 µm, Waters, Etten-Leur, the Netherlands) preceded by a 155 
KrudKatcher ULTRA HPLC in-line SS ﬁlter (0.5 µm × 0.1 mm I.D., Phenomenex, Torrance, 156 
USA). The mobile phase consisted of an optimized water-methanol-acetonitrile gradient at 0.3 157 
mL min-1 flow. The MS system operated in selected reaction monitoring (SRM) and positive 158 
mode during data acquisition. For each compound two transitions of the molecular ion 159 
[M+H]+ were monitored, one for quantification and the second for confirmation purposes. 160 
Analyte concentrations were quantified using the correspondent deuterated analogue. Specific 161 
LC-MS/MS parameters for compound identification can be found in Table SI-2.  162 
2.3.Calculations 163 
Phosphodiesterase type 5 inhibitors are the API in drugs used to treat erectile dysfunction 164 
(ED). Their classification within the ATC-system (Anatomic Therapeutic Chemical) 165 
corresponds to the group of genitourinary system and sex hormones (G), urological (04B), 166 
erectile dysfunction (E). The individual codes are necessary to find the national prescription 167 
and sales data of all formulations containing them as API despite the differences in brand 168 
name. The codes of the three approved substances included in the study and their established 169 
daily defined dose (DDD) can be found in Table 1. Sildenafil does not only have a 170 
registration as erectile stimulant, but also for pulmonary arterial hypertension. For this 171 
indication both the DDD and the number of prescriptions is lower. In the case of Belgium 172 
only the prescription data for the application of sildenafil as vasodilator antihypertensive 173 
(VA) was available. A similar trend in the prescription data was expected compared to the 174 
neighbouring country of The Netherlands and therefore the ratio ED/VA was extrapolated to 175 
estimate the number of prescriptions of sildenafil as erectile dysfunction drug in Belgium. 176 
The number of DDDs prescribed in the year 2015 (see Table 1) were multiplied by the DDD 177 
value in mg and converted into kg year-1. The kg of each API were multiplied by the urinary 178 
excretion factor (%) and divided by the country’s population and the L day-1 inh-1 estimated 179 
from the influent flow at the wastewater treatment plants included in the study (as a way of 180 
measuring the water use per inhabitant) (Carballa et al. 2008, Verlicchi et al. 2014). PECs 181 
were obtained in ng L-1. The excretion factors used in the calculation were gathered from 182 
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different pharmacokinetic studies. According to Muirhead and colleagues (Muirhead et al. 183 
2002) sildenafil is not excreted unchanged in urine, however in previous work it was found to 184 
account for up to a 10% in wastewater (Causanilles et al. 2016). The excretion ratios for its 185 
human urinary metabolites desmethyl- and desthylsildenafil were 3 and 22 % respectively. In 186 
the case of tadalafil, only a minor amount is excreted unchanged in urine (Phillips et al. 2004). 187 
In the case of vardenafil, approximately 0.7 – 3 % is excreted unchanged in urine, and its 188 
major metabolite component formed by N-deethylation, up to a 5 % (EMA 2005). 189 
The chemical analysis of the wastewater samples included in the study resulted in the MEC of 190 
each of the analytes in ng L-1. The ratio PEC/MEC was calculated to evaluate the accuracy of 191 
the environmental predictions (Verlicchi et al. 2014).  192 
The loads were obtained by multiplying the measured concentration in each sample in ng L-1 193 
by the daily influent flow rate at the WWTP in m3 24h-1. In order to normalize the load per 194 
1000 inhabitants, the obtained values in mg day-1 were divided by the population included in 195 
the catchment area. This normalization allows the direct comparison of results among the 196 
different communities included in the study. In the case of concentration values in real sample 197 
below LOQ, values were replaced by 0.5 × LOQ when at least one day in the week had a 198 
concentration value above the LOQ. Concentration values below LOD, as well as 199 
concentration values lower than LOQ when all values at that location were below LOQ, were 200 
set to 0.5 × LOD (Ort et al. 2014). The loads are expressed in mg day-1 1000 inh-1. 201 
Finally, sildenafil consumption was estimated from mass loads as indicated elsewhere 202 
(Venhuis et al. 2014b). The calculation was based on the available pharmacokinetic data and 203 
the assumption that there were no elimination processes such as degradation or sorption 204 
between the consumption point to the wastewater treatment plant, or dumping of unused 205 
drugs. Earlier stability studies confirmed there was not a statistically significant decrease in 206 
concentration of the target compounds after 48h storage at 4 °C (Causanilles et al. 2016). 207 
Statistical analysis of the data was performed using GraphPad Prism 5.  208 
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Table 1. Information of the investigated pharmaceuticals and national prescription data. 209 
Pharmaceutical ATC code DDD valuea (use) 
N° DDDs in 2015 
Belgium1 England2 Italy3 The Netherlands4 Norway5 
Sildenafil G04BE03 50 mg (ED)  











Tadalafil G04BE08 10 mg (ED) 85,276 9,120,725 13,314,239 1,570,918 2,203,956 
Vardenafil G04BE09 10 mg (ED) n.a. 1,262,350 n.a. 159,520 338,096 
VA: Vasodilator Antihypertensive 210 
ED: Erectile Dysfunction 211 
n.a.: not available 212 
a defined by the WHO Collaborating Centre for Drug Statistics Methodology, www.whocc.no 213 
b Estimated from the ED/VA ratio observed in the Netherlands 214 
Information source indicated with numbered superscript: 215 
 1 National Institute for Health and Disability Insurance, www.riziv.be 216 
2 National Health Service, www.nhsbsa.nhs.uk 217 
3 Agenzia Italina del Farmaco, www.agenziafarmaco.gov.it 218 
4 Dutch Foundation for Pharmaceutical Statistics, www.sfk.nl 219 
5 The Norwegian Institute of Public Health, www.norpd.no 220 
 221 
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3. Results and discussion 222 
3.1.Predicted and measured environmental concentrations  223 
The obtained PECs for the unchanged API sildenafil and its two urinary metabolites 224 
desmethyl- and desethylsildenafil are presented in Table 2 (the yearly prescribed kg are 225 
shown in Table SI-3). The highest predicted concentration was estimated for England, 226 
followed by The Netherlands, Norway and Italy with similar values, and the lowest was 227 
estimated for Belgium. PEC was not calculated for the API tadalafil, since the literature 228 
indicates that only a minor amount of the unchanged form was putatively identified in urine. 229 
This would result in a predicted concentration close to zero, which is below the limits of 230 
detection in wastewater for this compound. PECs for vardenafil and its metabolite, N-231 
desethylvardenafil were calculated for the countries with prescription data available, i.e. 232 
Norway, England and The Netherlands, although their presence in the environment was 233 
estimated to be minimal, below 1 ng L-1 (see Table SI-4). This predicted value is lower than 234 
their limits of detection in wastewater. 235 
 236 
Table 2. Predicted environmental concentrations (PECs) in wastewater influents for sildenafil 237 
and its two metabolites, expressed in ng L-1. 238 
Country 
PEC ng L-1 
Sildenafil Desmethylsildenafil Desethylsildenafil 
Belgium 3.0 ± 0.4 0.9 ± 0.1 7 ± 1 
England 25 ± 2 8 ± 1 56 ± 5 
Italy 8 ± 1 2.3 ± 0.3 17 ± 2 
The Netherlands 12.2 ± 0.4 3.7 ± 0.1 27 ± 1 
Norway 11 ± 1 3.3 ± 0.4 24 ± 3 
 239 
Results from the week-monitoring sampling campaign are reported in Table 3. Environmental 240 
concentrations per city are presented as the 7-d mean with standard deviation, expressed in ng 241 
L-1.  Method limits of quantification, in ng L-1, are included in the table. Sildenafil and its two 242 
human metabolites were quantified at different concentrations. Sildenafil was not detected in 243 
the samples collected in Castellon and Milan. In the city of Oslo only the Sunday sample was 244 
detected above the limit of quantification, and the rest were replaced by 0.5 × LOQ. Values 245 
were found in the range of 4 to 19 ng L-1. Desmethylsildenafil, the less abundant sildenafil 246 
metabolite, was not quantified in the cities of Castellon, Milan, Oslo and Zurich. In the cities 247 
of Copenhagen and Utrecht 2 and 4 days were <LOQ and replaced by 0.5 × LOQ. Values 248 
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were found in the range of 14 to 36 ng L-1. Desethylsildenafil, the most abundant metabolite 249 
of sildenafil, was detected and quantified in all samples. Values were found in the range of 5 250 
to 51 ng L-1. Neither the other two APIs included in the study, tadalafil and vardenafil, nor 251 
their metabolites and analogues were found above their limits of detection. The metabolite to 252 
parent concentration ratio was calculated when available. The ratio of desethylsildenafil to 253 
sildenafil ranged from 1.7 to 3.6 (6 cities, 2.8 ± 0.8). These results were in line with the range 254 
of ratios observed in the Dutch cities of Amsterdam, Eindhoven and Utrecht in the years 2013 255 
to 2015 (Causanilles et al. 2016). The ratio of desmethylsildenafil to sildenafil ratio ranged 256 
from 0.9 to 2.3 (4 cities, 1.6 ± 0.6). These results confirm literature findings because a lower 257 
ratio is expected for desmethylsildenafil, since it is the less abundant urinary metabolite 258 
(Muirhead et al. 2002).  259 
 260 
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Table 3. Measured environmental concentrations (MECs) expressed in ng L-1 with standard deviation (± SD) for 7 sampling days, n=7. 261 
Compounds LOD, ng L-1 LOQ, ng L-1 MEC (mean ± SD), ng L-1 
Bristol Brussels Castellon Copenhagen Milan Oslo Utrecht Zurich 
Sildenafil 2 6 12 ± 4 19 ± 3 (+) 14 ± 5 (+) 4 ± 2a 15 ± 4 9 ± 2 
Desmethylsildenafil 5 18 26 ± 7 36 ± 2 (+) 19 ± 8a (+) (+) 14 ± 4a (+) 
Desethylsildenafil 1 2 28 ± 8 33 ± 5 13 ± 3 51 ± 7 5 ± 1 8 ± 4 51 ± 4 32 ± 5 
Noracetildenafil 6 20 (-) (-) (-) (-) (-) (-) (-) (-) 
Tadalafil 2 8 (-) (-) (-) (-) (-) (-) (-) (-) 
Aminotadalafil 2 6 (-) (-) (-) (-) (-) (-) (-) (-) 
Chloropretadalafil 4 13 (-) (-) (-) (-) (-) (-) (-) (-) 
N-octylnortadalafil 30 100 (-) (-) (-) (-) (-) (-) (-) (-) 
Vardenafil 7 24 (-) (-) (-) (-) (-) (-) (-) (-) 
N-desethylvardenafil 9 30 (-) (-) (-) (-) (-) (-) (-) (-) 
a At least one value out of 7 is >LOQ; then the values <LOQ are replaced by 0.5 × LOQ  262 
(+) below limit of quantification but above limit of detection 263 
(-) below limit of detection 264 
 265 
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3.2.Comparison between PEC and MEC 266 
The PEC/MEC ratio was evaluated using the arbitrary criteria given below, in order to 267 
establish the accuracy of the prediction: 268 
o If 0.5 < PEC/MEC < 2, then the PEC is within reasonable boundaries of a value of 1 269 
(case (ii) explained in the introduction) 270 
o If PEC/MEC < 0.5, then the PEC is relatively low, indicative of case (iii) 271 
o If PEC/MEC > 2, then the PEC is relatively high, indicative of case (i) 272 
The results are graphically presented in Fig. 1. The ratio for sildenafil was only satisfactory in 273 
the Netherlands (0.9 ± 0.2), for Belgium it was too low and for England, Italy and Norway, 274 
too high. The ratio for desmethylsildenafil was satisfactory in Italy (0.9 ± 0.1) and Norway 275 
(1.3 ± 0.1), although one should realize that MEC was taken as 0.5 × LOD in order to be able 276 
to calculate the ratio, because in both cities the metabolite was found in all samples at levels 277 
below the LOQ. For the remaining cities in Belgium, England and The Netherlands, the ratio 278 
was too low. The ratio for desethylsildenafil was satisfactory in the Netherlands (0.5 ± 0.1), 279 
for Belgium it was too low and for England, Italy and Norway, too high.  280 
Two observations can be made from the evaluation of the PEC/MEC ratio. One is that in the 281 
case of Belgium, the predicted concentrations of sildenafil are much lower than the actual 282 
concentrations measured in wastewater. Although this may have been caused by unregistered 283 
use of sildenafil (case iii, see introduction), one should bear in mind that for the calculation of 284 
PEC in this case the estimation of prescribed DDDs was obtained by extrapolation from the 285 
Dutch ED/VA trend, because actual DDD data were lacking. The actual ED/VA ratio for 286 
Belgium may be different of course. One other possible reason for obtaining relatively low 287 
PECs is if during the sampling week heavy rainfall would have occurred. However, 288 
meteorological records for the city of Brussels (Ukkel station) showed that in the actual week 289 
of sampling almost no rainfall occurred.  290 
The second observation corresponds to the three countries England, Italy and Norway, where 291 
both sildenafil and desethylsildenafil show a high PEC/MEC ratio. This translates into lower 292 
measured concentrations than what is predicted from national prescription data. This could be 293 
explained by the non-consumption of the total prescribed amount or by a higher degradation 294 
or sorption of the compounds in the local sewer systems. We currently don’t have reasons to 295 
substantiate the likeliness of higher rates of in-sewer degradation in these countries. 296 
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Overall, the comparison results should be handled with care since wastewater analysis was 297 
performed only in one city per country in a limited time period (7 consecutive days), and 298 
therefore the extrapolation of results to the whole country will be biased by the specific spatial 299 
and temporal profiles of that city (versus other areas within the countries). 300 
 301 
 302 
Fig. 1. Comparison of predicted and measured concentrations in influent wastewaters, 303 
expressed as the PEC/MEC ratio. Dotted lines at y = 0.5 and 2 represent the criteria limits. 304 
 305 
For tadalafil and vardenafil the ratio PEC/MEC could not be calculated per se because of the 306 
minimal excretion ratios and non-detects in all wastewater samples. However, results of the 307 
measurements are in line with what was predicted based on prescription data because these 308 
PECs would also fall below the actual limits of detection. 309 
 310 
3.3.Daily loads and back-calculated consumption 311 
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MEC were translated into loads in mg day-1 and normalized to 1000 inhabitants to allow a 312 
better comparison between the cities included in the study. The 7-day mean for each city with 313 
standard deviation is presented in Table 4. The highest normalized sildenafil load was found 314 
in the city of Brussels closely followed by Zurich and Copenhagen. Compared to these cities, 315 
a medium load was found in Bristol and Utrecht, and the lowest levels were observed in 316 
Milan and Castellón. For the metabolites a similar trend was found, in accordance with their 317 
excretion ratios. The daily variations are presented in Fig. 2, expressed as percentages of the 318 
total load. No significant increase in loads was found in weekend samples compared to 319 
weekday samples, reaffirming the use of sildenafil as needed and not with a clear recreational 320 
aim. This phenomenon known as “weekend effect” is very typical for illicit drugs such as 321 
cocaine or ecstasy (MDMA) (Causanilles et al. 2017, Salvatore et al. 2015).  322 
Taking into account the loads for sildenafil and its two metabolites, it is possible to back-323 
calculate into sildenafil consumption by the population connected to the studied sewer system. 324 
This estimation was done as explained elsewhere (Venhuis et al. 2014a). The estimated 325 
consumption of sildenafil in mg week-1 1000inh-1 back-calculated from wastewater loads 326 
arranged the cities in the following order (from higher to lower use, and including previously 327 
published results from other Dutch cities (Causanilles et al. 2016)): Amsterdam, 872; 328 
Copenhagen, 542; Brussels, 517; Zurich, 439; Eindhoven, 432; Bristol, 365; Utrecht, 292; 329 
Oslo, 145; Castellon, 100; and Milan, 87.  330 
The comparison from the obtained sildenafil consumption from wastewater and the 331 
prescription data showed that only in the case of Brussels (where the prescription data was 332 
estimated by extrapolating the Dutch trend) and Utrecht, the estimated consumption from 333 
wastewater was higher than what could be explained by the national prescription data. In the 334 
cities of Amsterdam and Eindhoven previously published results (Causanilles et al. 2016), 335 
showed an even higher consumption, that could not be explained by national sales data, 336 
ranging up to 85% and 70%, respectively.  In Bristol the predicted and measured values were 337 
in good agreement. In Milan and Oslo the estimated consumption from wastewater was lower 338 
than what could be explained by the prescription data. The final evaluation of the correlation 339 
between wastewater data and prescription data was found to be non-significant by Spearman’s 340 
correlation coefficient (ρ = -0.30) with p-value above 0.05 (p = 0.68) (see Fig. SI-1). 341 
 342 
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Table 4. Measured loads expressed in mg day-1 with standard deviation (± SD) for 7 sampling days, n=7. 343 
 Loads (mean ± SD), mg day-1 1000 inh-1 
 Bristol Brussels Castellon Copenhagen Milan Oslo Utrecht Zurich 
Sildenafil 2.8 ± 1.1 5.1 ± 1.0 0.23 ± 0.03 b 3.8 ± 1.2 0.4 ± 0.1 b 1.7 ± 0.7 a 2.4 ± 0.7 4.2 ± 1.5 
Desmethylsildenafil 6.2 ± 1.7 9.4 ± 1.3 0.6 ± 0.1 b 5.3 ± 1.9 a 1.0 ± 0.2 b 1.2 ± 0.1 b 2.1 ± 0.9 a 1.1 ± 0.2 b 
Desethylsildenafil 6.6 ± 2.1 8.5 ± 1.2 3.0 ± 0.6 13.7 ± 1.7 2.1 ± 0.5 3.7 ± 1.5 8.0 ± 0.5 13.9 ± 3.1 
a At least one value out of 7 is >LOQ then when <LOQ replaced by 0.5 × LOQ  344 
b All values <LOQ then replaced by 0.5 × LOD 345 
 346 
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Fig.2. Daily variations expressed as the percentage of the total load, combining results for the 8 cities. The box represents the median, 25% and 348 
75% percentile values and the error bars extend to the minimum and maximum values. The coloured lines represent each of the cities. 349 
350 
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 351 
Fig. 3. Comparison of the estimated consumption of sildenafil from wastewater loads (WW, 352 
blue coloured bars) and prescription data (DDDs, red coloured bars). For Spain, Denmark and 353 
Switzerland no prescription data was available. 354 
 355 
4. Conclusions 356 
The present study is the first to compare the use of the erectile dysfunction products in 357 
different European cities through chemical analysis of wastewater. The analysis of influents 358 
revealed the presence of sildenafil and its two human metabolites in all cities sampled with 359 
average loads varying between 0.2 and 14ௗmgௗday−1 1000 inh−1. None of the other ED 360 
products analysed were observed in concentrations above the method detection limits. While 361 
it is known that sildenafil is available in products from illegal sources such as internet shops, 362 
the results of the present study show that consumption beyond prescribed doses is not 363 
common across Europe. Despite the limitations related to the assessment of both predicted 364 
and measured loads, it seems that the populations in Utrecht (and also in other cities in The 365 
Netherlands) and in Brussels might be more inclined towards the use of products from illegal 366 
sources or rogue online pharmacies than in the other three European cities included in the 367 
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study for which prescription data were available (Bristol, Milan and Oslo). After this first 368 
study illustrating the potential of wastewater-based epidemiology in this field, further research 369 
will allow to improve the application of this approach for investigating the use of rogue 370 
pharmacies and counterfeit medication. 371 
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